Previous studies have described RGC-32 upregulation in ovarian, colon, breast and prostate cancers indicating that deregulation of the cell cycle by RGC-32 may play a key role in the aetiology of a diverse range of tumours [31]–[33]. This evidence concerns the gene RGCC and neoplasm.